DGIdb - PROCAINAMIDE Drug Record

PROCAINAMIDE chembl:CHEMBL640 Approved

Alternate Names:

PRONESTYL-SR
PROCAN
PROCAPAN
PRONESTYL
NSC-27461
PROCANBID
PROCAINAMIDE
BIOCORYL
P-AMINOBENZOIC DIETHYLAMINOETHYLAMIDE
PRONESTYL®
PROCAINAMIDA
PROCAINAMIDUM
P-AMINO-N-(2-DIETHYLAMINOETHYL)BENZAMIDE
PROCAN®
chembl:CHEMBL640
drugbank:01035
chemidplus:51-06-9
pubchem.compound:4913
rxcui:8700

Drug Info:

Drug Categories	highest risk qtc-prolonging agents
Drug Categories	antiarrhythmics, class ia
Drug Groups	approved
FDA Approval	1951
Drug Class	small molecule
Drug Indications	Anti-Arrhythmia Agents
Year of Approval	1951
Drug Class	anti-arrhythmia agents
Drug Categories	agents causing muscle toxicity
Drug Categories	agents that produce neuromuscular block (indirect)
Drug Categories	antiarrhythmic agents
Drug Categories	antiarrhythmics, class i
Drug Categories	benzamides and benzamide derivatives
Drug Categories	cholinesterase inhibitors
Drug Categories	cytochrome p-450 cyp2d6 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 substrates
Drug Categories	drugs that are mainly renally excreted
Drug Categories	drugs that are mainly renally excreted with narrow therapeutic index
Drug Categories	mate 1 substrates
Drug Categories	mate 1 substrates with a narrow therapeutic index
Drug Categories	mate 2 substrates
Drug Categories	mate 2 substrates with a narrow therapeutic index
Drug Categories	mate substrates
Drug Categories	narrow therapeutic index drugs
Drug Categories	oct1 inhibitors
Drug Categories	oct2 inhibitors
Drug Categories	oct2 substrates with narrow therapeutic index
Drug Categories	qtc prolonging agents

(2 More Sources)

Publications:

Chen et al., 2000, Brugada syndrome without mutation of the cardiac sodium channel gene in a Taiwanese patient., J. Formos. Med. Assoc.
Brugada et al., 1999, The syndrome of right bundle branch block ST segment elevation in V1 to V3 and sudden death--the Brugada syndrome., Europace
Weiss et al., 2002, Clinical and molecular heterogeneity in the Brugada syndrome: a novel gene locus on chromosome 3., Circulation
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Brugada et al., 1999, [Brugada syndrome]., Arch Mal Coeur Vaiss
Brugada et al., 2000, Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts., Circulation
Lee et al., 2005, Procainamide is a specific inhibitor of DNA methyltransferase 1., J. Biol. Chem.
Oelke et al., 2004, Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors., Arthritis Rheum.
Scheinbart et al., 1991, Procainamide inhibits DNA methyltransferase in a human T cell line., J. Rheumatol.
Januchowski et al., 2005, Effect of 5-azacytidine and procainamide on CD3-zeta chain expression in Jurkat T cells., Biomed. Pharmacother.
Chiu et al., 2004, Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels., J. Pharmacol. Sci.

PROCAINAMIDE RFWD2

Interaction Score: 2.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
PROCAINAMIDE DNMT1

Interaction Score: 1.83

Interaction Types & Directionality:

other/unknown

Interaction Info:

PMIDs:
16230360 15188362 2066944 15795105

Sources:
DrugBank
PROCAINAMIDE SCN5A

Interaction Score: 1.22

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
11155778 11225790 11839626 11752352 10443304 10662748

Sources:
TEND PharmGKB TdgClinicalTrial DrugBank
PROCAINAMIDE NAT2

Interaction Score: 0.63

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PROCAINAMIDE KCNH2

Interaction Score: 0.06

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
15272206

Sources:
DrugBank

DrugBank: DB01035

Version: 5.1.7

Alternate Names:

PROCAINAMIDE DrugBank Drug Name

51-06-9 CAS Number

Apo-procainamide Cap 250mg Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories acids, carbocyclic

Publications:

Chiu et al., 2004, Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels., J. Pharmacol. Sci.

Chen et al., 2000, Brugada syndrome without mutation of the cardiac sodium channel gene in a Taiwanese patient., J. Formos. Med. Assoc.

Brugada et al., 1999, The syndrome of right bundle branch block ST segment elevation in V1 to V3 and sudden death--the Brugada syndrome., Europace

TEND: PROCAINAMIDE
- Version: 01-August-2011
Alternate Names:

PROCAINAMIDE Primary Drug Name

Drug Info:

Drug Class anti-arrhythmia agents

Year of Approval 1951

Publications:
TdgClinicalTrial: PROCAINAMIDE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Anti-Arrhythmia Agents

Drug Class small molecule

FDA Approval 1951

Publications:
TTD: Procainamide
- Version: 2020.06.01
Alternate Names:

D0U5SI TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL640
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
PharmGKB: procainamide
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

PROCAINAMIDE	DrugBank Drug Name
51-06-9	CAS Number
Apo-procainamide Cap 250mg	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Categories	acids, carbocyclic

Trial Name	-
Novel drug target	Established target

PROCAINAMIDE Drug Record

PROCAINAMIDE chembl:CHEMBL640 Approved

Alternate Names:

Drug Info:

Publications:

PROCAINAMIDE RFWD2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

PROCAINAMIDE DNMT1

Interaction Types & Directionality: other/unknown

Interaction Info:

PMIDs: 16230360 15188362 2066944 15795105

Sources: DrugBank

PROCAINAMIDE SCN5A

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 11155778 11225790 11839626 11752352 10443304 10662748

Sources: TEND PharmGKB TdgClinicalTrial DrugBank

PROCAINAMIDE NAT2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

PROCAINAMIDE KCNH2

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 15272206

Sources: DrugBank

DrugBank: DB01035

Alternate Names: PROCAINAMIDE DrugBank Drug Name 51-06-9 CAS Number Apo-procainamide Cap 250mg Drug Brand

Drug Info: Drug Type small molecule Drug Groups approved Drug Categories acids, carbocyclic

TEND: PROCAINAMIDE

Alternate Names: PROCAINAMIDE Primary Drug Name

Drug Info: Drug Class anti-arrhythmia agents Year of Approval 1951

Publications:

TdgClinicalTrial: PROCAINAMIDE

Alternate Names:

Drug Info: Drug Indications Anti-Arrhythmia Agents Drug Class small molecule FDA Approval 1951

Publications:

TTD: Procainamide

Alternate Names: D0U5SI TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL640

Alternate Names:

Drug Info:

Publications:

PharmGKB: procainamide

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

other/unknown

PMIDs:
16230360 15188362 2066944 15795105

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
11155778 11225790 11839626 11752352 10443304 10662748

Sources:
TEND PharmGKB TdgClinicalTrial DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
15272206

Sources:
DrugBank

Alternate Names:

PROCAINAMIDE DrugBank Drug Name

51-06-9 CAS Number

Apo-procainamide Cap 250mg Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories acids, carbocyclic

Alternate Names:

PROCAINAMIDE Primary Drug Name

Drug Info:

Drug Class anti-arrhythmia agents

Year of Approval 1951

Drug Info:

Drug Indications Anti-Arrhythmia Agents

Drug Class small molecule

FDA Approval 1951

Alternate Names:

D0U5SI TTD Drug ID